These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

790 related articles for article (PubMed ID: 36551958)

  • 1. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
    Tümen D; Heumann P; Gülow K; Demirci CN; Cosma LS; Müller M; Kandulski A
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence.
    Cerreto M; Cardone F; Cerrito L; Stella L; Santopaolo F; Pallozzi M; Gasbarrini A; Ponziani FR
    Curr Oncol; 2023 Sep; 30(10):8774-8792. PubMed ID: 37887533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.
    Xie DY; Ren ZG; Zhou J; Fan J; Gao Q
    Hepatobiliary Surg Nutr; 2020 Aug; 9(4):452-463. PubMed ID: 32832496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
    Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.
    Su TH; Wu CH; Liu TH; Ho CM; Liu CJ
    Clin Mol Hepatol; 2023 Apr; 29(2):230-241. PubMed ID: 36710607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma: Current Concepts in Diagnosis, Staging and Treatment.
    Schütte K; Schulz C; Malfertheiner P
    Gastrointest Tumors; 2014 Jun; 1(2):84-92. PubMed ID: 26672483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated treatment approach to hepatocellular carcinoma.
    Llovet JM
    J Gastroenterol; 2005 Mar; 40(3):225-35. PubMed ID: 15830281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience With Changing Etiology and Nontransplant Curative Treatment Modalities for Hepatocellular Carcinoma in a Real-Life Setting-A Retrospective Descriptive Analysis.
    Tohra S; Duseja A; Taneja S; Kalra N; Gorsi U; Behera A; Kaman L; Dahiya D; Sahu S; Sharma B; Singh V; Dhiman RK; Chawla Y
    J Clin Exp Hepatol; 2021; 11(6):682-690. PubMed ID: 34866847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
    Jindal A; Thadi A; Shailubhai K
    J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
    Choi JY
    Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma.
    Wang CH; Wey KC; Mo LR; Chang KK; Lin RC; Kuo JJ
    Asian Pac J Cancer Prev; 2015; 16(9):3595-604. PubMed ID: 25987009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Therapies for Hepatocellular Carcinoma (HCC).
    Chakraborty E; Sarkar D
    Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?
    Himmelsbach V; Koch C; Trojan J; Finkelmeier F
    J Hepatocell Carcinoma; 2024; 11():363-372. PubMed ID: 38405324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.